SEC Company Response from Nutex Health, Inc. (NUTX) (CIK 0001479681) (NUTX) — Sep 20, 2018
Nutex Health, Inc. (NUTX) (CIK 0001479681)
Date: Sept. 20, 2018 · CIK: 0001479681 · Accession: 0001607062-18-000287
AI Filing Summary & Sentiment
Referenced dates: September 4, 2018
Letter
Division of Corporation Finance United States Securities and Exchange Commission Re: iGambit, Inc. Information Statement on Schedule 14(c) Filed August 9, File No. 0-53862
Dear Mr. Hamidi:
On behalf of iGambit, Inc. (the “Company”), we are writing in response to the comments of the staff of the Commission (the “Staff”) on the Schedule 14(c) filing as transmitted by a letter dated September 4, 2018 (the “Comment Letter”) to John Salerno, Chief Executive Officer of the Company and an additional oral discussion with Mr. Hamidi on September 20, 2018. The answers set forth herein refer to each of the Staff’s comments by number. This letter sets forth the Company’s response to Item 1. of the Comment Letter. An amended filing to the preliminary Schedule 14(c) Filing (the “Amended 14(c) Filing”) reflecting changes in response to your comments is being filed via the Commission’s EDGAR system.
General
1. In your Form 8-K filed August 6, 2018, you state that your designation and subsequent issuance of Series A Preferred Stock to CEO John Salerno on August 2, 2018 “gives him effective control over [your] affairs.” Please amend this Form 8-K to provide the disclosure required by Item 5.01 of Form 8-K for a change in control, and also revise the instant information statement to provide the disclosure required by Item 6(e) of Schedule 14A.
Response: We provided Item 6(e) disclosure of Schedule 14A. in an Amended 14(c) Filing. A marked courtesy copy has been sent to Mr. Hamidi.
**************
Please feel free to contact the undersigned at 954-991-5426 with any questions.
Very
truly yours,
/s/
Joel D. Mayersohn
Show Raw Text
CORRESP
1
filename1.htm
September
20, 2018
VIA
SEC EDGAR
Division
of Corporation Finance
United
States Securities and Exchange Commission
100 F
Street, N.E.
Washington,
D.C. 20549
Attn:
Parhaum J. Hamidi,
Special Counsel
Mara L. Ransom
Re:
iGambit, Inc.
Information Statement
on Schedule 14(c)
Filed August 9,
2018
File No. 0-53862
Dear Mr. Hamidi:
On
behalf of iGambit, Inc. (the “Company”), we are writing in response to the comments of the staff of the Commission
(the “Staff”) on the Schedule 14(c) filing as transmitted by a letter dated September 4, 2018 (the “Comment
Letter”) to John Salerno, Chief Executive Officer of the Company and an additional oral discussion with Mr. Hamidi on
September 20, 2018. The answers set forth herein refer to each of the Staff’s comments by number. This letter sets forth
the Company’s response to Item 1. of the Comment Letter. An amended filing to the preliminary Schedule 14(c) Filing (the
“Amended 14(c) Filing”) reflecting changes in response to your comments is being filed via the Commission’s
EDGAR system.
General
1. In
your Form 8-K filed August 6, 2018, you state that your designation and subsequent issuance
of Series A Preferred Stock to CEO John Salerno on August 2, 2018 “gives him effective
control over [your] affairs.” Please amend this Form 8-K to provide the disclosure
required by Item 5.01 of Form 8-K for a change in control, and also revise the instant
information statement to provide the disclosure required by Item 6(e) of Schedule 14A.
Response:
We provided Item 6(e) disclosure of Schedule 14A. in an Amended 14(c) Filing. A marked courtesy copy has been sent to
Mr. Hamidi.
**************
Please
feel free to contact the undersigned at 954-991-5426 with any questions.
Very
truly yours,
/s/
Joel D. Mayersohn